Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Intangibles (2022)

NewAmsterdam Pharma's Intangibles history spans 1 years, with the latest figure at $84.8 million for Q4 2022.

  • For Q4 2022, Intangibles changed N/A year-over-year to $84.8 million; the TTM value through Dec 2022 reached $84.8 million, changed N/A, while the annual FY2022 figure was $84.8 million, N/A changed from the prior year.
  • Intangibles for Q4 2022 was $84.8 million at NewAmsterdam Pharma.
  • Across five years, Intangibles topped out at $84.8 million in Q4 2022 and bottomed at $84.8 million in Q4 2022.